Jun 11, 2024
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Read More...
Jun 10, 2024
Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...
Read More...
Jun 07, 2024
Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...
Read More...
Jun 06, 2024
Stryker Released LIFEPAK 35 Monitor/Defibrillator On June 04, 2024, Stryker, a global leader in medical technologies, announced the launch of the LIFEPAK 35 monitor/defibrillator. This latest addition to their monitor/defibrillator lineup features advanced technology and is designed on an intuitive, modern...
Read More...
Jun 05, 2024
The advancement of technology has ushered in an era where the fusion of biology and electronics is becoming increasingly seamless. One of the most groundbreaking innovations in this domain is wireless brain sensors. These devices promise to revolutionize neuroscience research, enhance healthcare delivery, and impro...
Read More...
Jun 04, 2024
FDA Greenlights Moderna's RSV Vaccine mRESVIA(R) Moderna, Inc. has announced that the FDA has approved mRESVIA (mRNA-1345), an mRNA-based vaccine for respiratory syncytial virus (RSV), to protect adults aged 60 and over from lower respiratory tract infections caused by RSV. This approval, granted under a breakth...
Read More...
Jun 03, 2024
Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US an...
Read More...
May 31, 2024
The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...
Read More...
May 30, 2024
Solis Mammography Announced Acquisition of MUSIC Imaging Center in Gainesville, Florida On May 28, 2024, Solis Mammography announced the acquisition of the MUSIC Mammography and Ultrasound Imaging Center in Gainesville, Florida. For more than 10 years, MUSIC has provided patients with an advanced standard ...
Read More...
May 29, 2024
Artificial blood vessels are at the forefront of medical innovation, offering a lifeline to millions worldwide. With advancements in bioengineering, these synthetic conduits are shaping a new era in healthcare, promising solutions to cardiovascular diseases and beyond. Artificial blood vessels represent a revolu...
Read More...